Goldberg Robert J, Spencer Frederick A, Farmer Cheryl, Lessard Darleen, Pezzella Stephen M, Meyer Theo E
Department of Medicine, Division of Cardiovascular Medicine, University of Massachusetts Medical School, Worcester, Mass, USA.
Am J Med. 2007 Jan;120(1):98.e1-8. doi: 10.1016/j.amjmed.2006.05.051.
Little data are available about the hospital management of patients with decompensated heart failure (HF) with individual and combination medical therapies, particularly from the more generalizable perspective of a population-based investigation. The purpose of our study was to describe the use of different cardiac medications in 2463 patients with new-onset HF who were discharged from all greater Worcester, Massachusetts, hospitals during 2000.
On the basis of a review of medical records, we examined the prescribing of 2 classes of cardiac medications that have been shown to improve the long-term prognosis of patients with HF (angiotensin pathway inhibitors and beta-blockers). We also examined the use of 2 therapies commonly used to improve the symptomatic status of patients with acute HF (diuretics and digoxin).
The mean age of the study sample was 76 years, and 57% were women. Approximately 1 in 5 patients were not prescribed beta-blockers or angiotensin inhibitors during their index hospitalization, whereas 1 in 3 patients were discharged with both of these effective cardiac medications. Diuretics were prescribed for virtually all patients (98%), followed by the use of digoxin in approximately half of patients (48%). The receipt of both beta-blockers and angiotensin pathway inhibitors was associated with several demographic, medical history, and clinical factors. Patients treated with both effective cardiac medications were also more likely to be counseled to monitor or modify several lifestyle factors that have been shown to be effective adjuncts to the medical management of patients with HF.
Considerable opportunity remains for the more optimal hospital management of patients with decompensated HF.
关于失代偿性心力衰竭(HF)患者采用个体化及联合药物治疗的医院管理方面的数据较少,尤其是从基于人群调查的更具普遍性的角度来看。我们研究的目的是描述2000年期间从马萨诸塞州伍斯特市所有大医院出院的2463例新发HF患者中不同心脏药物的使用情况。
基于病历审查,我们检查了已证明可改善HF患者长期预后的两类心脏药物(血管紧张素途径抑制剂和β受体阻滞剂)的处方情况。我们还检查了常用于改善急性HF患者症状状态的两种治疗方法(利尿剂和地高辛)的使用情况。
研究样本的平均年龄为76岁,57%为女性。约五分之一的患者在其首次住院期间未开具β受体阻滞剂或血管紧张素抑制剂,而三分之一的患者出院时同时使用了这两种有效的心脏药物。几乎所有患者(98%)都开具了利尿剂,约一半患者(48%)使用了地高辛。同时接受β受体阻滞剂和血管紧张素途径抑制剂与多种人口统计学、病史和临床因素相关。接受两种有效心脏药物治疗的患者也更有可能接受建议,以监测或改变几种已被证明是HF患者药物治疗有效辅助手段的生活方式因素。
失代偿性HF患者的医院管理仍有很大的优化空间。